G1 Therapeutics Inc (GTHX) - News Archive

Breaking NewsSeptember 5, 2024 – Exciting developments in the biopharmaceutical landscape as Pharmacosmos Group and G1 Therapeutics Inc. (NASDAQ: GTHX) announce the successful closing of their tender offer. This pivotal...

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period: A New Era for Major Pharmaceutical Preparations?Pharmacosmos Group, a Danish pharmaceutical company specializing in innovat...

Evaluation of Trilaciclib s Efficacy and Safety in mTNBC Patients: Insights from the Phase 3 PRESERVE 2 Trial Metastatic Triple Negative Breast Cancer (mTNBC) represents a substantial medical challenge due to its aggres...

In a groundbreaking move, G1 Therapeutics and Deimos Biosciences have recently announced a momentous global licensing agreement for Lerociclib, destined to reshape the landscape of radioprotective treatments. This agree...

In a groundbreaking move for the pharmaceutical industry, G1 Therapeutics and Pepper Bio have recently announced a monumental global licensing agreement for the revolutionary drug, Lerociclib. Marking an unprecedented c...

aims to present the latest advancements in pharmaceutical research and development. This article provides an analysis of two recent articles on the continuation of the pivotal Phase 3 trial of Trilaciclib in treating me...

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 - G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, has recently made...

In a world where advancements in medical research are constantly underway, the fight against breast cancer has seen significant breakthroughs. Recently, G1 Therapeutics presented groundbreaking data at the 2023 San Anto...